Related Experiment Video
Updated: May 20, 2026
10:29
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Risk factors for raltegravir resistance development in clinical practice
Isabelle Malet1, Slim Fourati, Laurence Morand-Joubert
1Laboratoire de Virologie, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, UPMC Université Pierre et Marie Curie, INSERM U943, Paris, France. isabelle.malet@psl.aphp.fr
The Journal of Antimicrobial Chemotherapy
|July 6, 2012
Summary
To prevent raltegravir resistance, HIV patients should use at least two active drugs with raltegravir and maintain viral loads below 200 copies/mL. This strategy minimizes the selection of crucial resistance mutations.
Area of Science:
- Infectious Diseases
- Virology
- Pharmacology
Background:
- Raltegravir is a key integrase inhibitor for HIV-1 treatment.
- The emergence of resistance mutations can compromise treatment efficacy.
- Understanding optimal raltegravir use is crucial for long-term HIV management.
Purpose of the Study:
- To identify optimal conditions for raltegravir use to prevent resistance.
- To investigate factors influencing the selection of raltegravir resistance mutations (148, 155, 143 pathways).
Main Methods:
- Retrospective study of 161 patients experiencing raltegravir treatment failure.
- Analysis of baseline and failure parameters including viral load, CD4 count, and genotypic sensitivity score (GSS).
- Logistic regression used to identify factors associated with resistance mutation emergence; phenotypic susceptibility tested in a subset.
Main Results:
- 28.6% of patients developed integrase resistance mutations.
- High HIV-1 viral load (>200 copies/mL) at failure and low GSS (<2) were independently associated with resistance.
- Patients with viral load ≤200 copies/mL had significantly lower mutation rates (7.7%) compared to those >200 copies/mL (48.1%).
Conclusions:
- Maintaining HIV-1 viral load ≤200 copies/mL is critical to avoid raltegravir resistance.
- Combining raltegravir with at least two active drugs is recommended to prevent resistance.
- These findings support optimized raltegravir treatment strategies for durable viral suppression.
Related Concept Videos
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:24Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
01:25Clinical Significance of Antibiotic Resistance
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
00:36Viral Mutations
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material for adaptive...
02:33Retroviruses
Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...